This inventor holds 2 USPTO granted patents and 2 published patent applications. Top assignees: Cambridge Enterprise Limited, University of Cambridge. Active years: 2024-2026.
Company Filing History:
Years Active: 2024-2026
Title: Paul Brear: Innovator in Pharmaceutical Chemistry
Introduction
Paul Brear is a notable inventor based in Cambridgeshire, GB. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on benzo[c][2,6]naphthyridine derivatives.
Latest Patents
Brear holds a patent for "Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof." This patent includes a compound of the formula: (5-(2-(4-((3,5-difluoro-4-(trifluoromethoxy)benzyl)amino)butoxy)ethoxy)benzo[c][2,6]naphthyridine-8-carboxylic acid) or a pharmaceutically acceptable salt thereof. The patent also covers a pharmaceutical composition comprising the above compound, or a pharmaceutically acceptable salt thereof, along with a pharmaceutically acceptable excipient.
Career Highlights
Paul Brear is associated with Cambridge Enterprise Limited, where he applies his expertise in pharmaceutical innovations. His work has contributed to advancements in therapeutic applications, showcasing his commitment to improving healthcare solutions.
Collaborations
Brear has collaborated with notable colleagues, including Marko Juhana Hyvonen and David Robert Spring. These partnerships have fostered a collaborative environment that enhances the development of innovative pharmaceutical solutions.
Conclusion
Paul Brear's contributions to pharmaceutical chemistry through his patent and collaborations highlight his role as an innovator in the field. His work continues to impact therapeutic advancements, demonstrating the importance of innovation in healthcare.